On 3 July 2007 the Spanish parliament approved the Biomedical Research Act. This article discusses the provisions of the Biomedical Research Act that are directly relevant for the regulatory framework of biobanks in Spain. This means that we are not only interested in the procedural and administrative dispositions governing biobanks. Our main preoccupation relates to the substantial provisions governing the collection, the research use and the conservation of biological samples. Our contribution starts in the second part with a brief description of the definition of "biobank" in the Spanish Act. Subsequently, in the third part, we deal extensively with the legal conditions for the collection, use and conservation of biological samples and accompanying data for biomedical research purposes. In the fourth part we examine the specific legal framework of research biobanks in Spain, with a special focus on the source's right to know or not to know, his right to privacy and his right to non-discrimination. A discussion of the main characteristics of the Act and some conclusions finalise this article. In stead of summarising these conclusions in our own words, we prefer to cite the legislator who stated in the preamble to the Act the following: "The regulation on the obtaining, conservation, use and assignment of biological samples is likewise object of a detailed regulation. As is logical, the legal framework turns once again on the consent of the source of the samples and on the previous information that must be provided to this respect. In so far as the disjunctive on the possibility to grant a completely generic or a specific consent on the use or latter uses of the sample, the Law has chosen an intermediate and flexible regulation, in that the initial consent may provide coverage, if in the information previously provided to the subject source there has been a provision about later researches related with the initial, including the researches that may be undertaken by third parties and the assignment of the data or of identified or identifiable samples to them".
Download full-text PDF |
Source |
---|
J Phys Act Health
January 2025
Mackenzie Wearables Research Hub, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Background: There are no studies examining the prospective joint association of device-based measures of sedentary time and physical activity (PA) with cancer mortality. We examined the joint associations of sedentary time and intensity-specific PA with cancer mortality in 72,458 adults from UK Biobank.
Methods: Participants wore an Axivity AX3 accelerometer on their dominant wrist for at least 3 days (with at least 1 weekend day).
Alzheimers Res Ther
January 2025
Laboratory for Clinical Neuroscience, Center for Biomedical Technology, Universidad Politécnica de Madrid, IdISSC, Crta M40, km38, Madrid, 28223, Spain.
Background: Dementia patients commonly present multiple neuropathologies, worsening cognitive function, yet structural neuroimaging signatures of dementia have not been positioned in the context of combined pathology. In this study, we implemented an MRI voxel-based approach to explore combined and independent effects of dementia pathologies on grey and white matter structural changes.
Methods: In 91 amnestic dementia patients with post-mortem brain donation, grey matter density and white matter hyperintensity (WMH) burdens were obtained from pre-mortem MRI and analyzed in relation to Alzheimer's, vascular, Lewy body, TDP-43, and hippocampal sclerosis (HS) pathologies.
J Med Genet
January 2025
Department of Gastroenterology, Hospital Clínic de Barcelona, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Institut Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Br J Haematol
January 2025
Department of Research, Østfold Hospital Trust, Grålum, Norway.
There is no diagnostic test for primary immune thrombocytopenia (ITP). Certain microRNAs have shown to have diagnostic potential in ITP. We validated 12 microRNAs identified from two previous studies to find a diagnostic biomarker.
View Article and Find Full Text PDFJAGN1 (Jagunal-homolog1) is a ER-resident transmembrane protein which is part of the early secretory pathway and granulocyte colony-stimulating factor receptor mediated signaling. Autosomal recessively inherited variants in the JAGN1 gene lead to congenital neutropenia, early-onset bacterial infections, aphthosis and skin abscesses due to aberrant differentiation and maturation of neutrophils. In addition, bone metabolism disorders and a syndromic phenotype, including facial features, short stature and neurodevelopmental delay, have been reported in affected patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!